IRIS
DE ANGELIS, CARMINE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 46
NA - Nord America 14
SA - Sud America 5
EU - Europa 4
Totale 69
Salva come PNG Salva come JPEG
Nazione #
SG - Singapore 36
MX - Messico 7
HK - Hong Kong 6
US - Stati Uniti d'America 6
BR - Brasile 5
IT - Italia 4
IN - India 2
BD - Bangladesh 1
IQ - Iraq 1
TT - Trinidad e Tobago 1
Totale 69
Salva come PNG Salva come JPEG
Città #
Singapore 9
Mexico City 7
Hong Kong 6
Baghdad 1
Brooklyn 1
Butler 1
Caxias do Sul 1
Chennai 1
Conyers 1
Curitiba 1
Delhi 1
Dhaka 1
Grundy 1
Osasco 1
Palatine 1
Port of Spain 1
Propriá 1
Winnsboro 1
Totale 37
Salva come PNG Salva come JPEG
Nome #
Definition of High-Risk Early Hormone-Positive HER2-Negative Breast Cancer: A Consensus Review 5
Evaluation of a Four-Gene Panel for Hereditary Cancer Risk Assessment 4
Breast cancer prognosis in BRCA1/2 mutation carriers: A case control study 3
HER2 reactivation through acquisition of the HER2 L755S mutation as a mechanism of acquired resistance to HER2-targeted therapy in HER2+ breast cancer 3
New steps on an old path: Novel estrogen receptor inhibitors in breast cancer 3
Prognostic and clinical impact of the endocrine resistance/sensitivity classification according to international consensus guidelines for advanced breast cancer: an individual patient-level analysis from the Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM) studies 3
A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer 3
Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models 3
Intermediate clinical endpoints in early-stage breast cancer: an analysis of individual patient data from the Gruppo Italiano Mammella and Mammella Intergruppo trials 3
Case Report: Detection of a Novel Germline PALB2 Deletion in a Young Woman With Hereditary Breast Cancer: When the Patient's Phenotype History Doesn't Lie 3
Tumor characteristics and prognosis in familial breast cancer 3
Efficacy of PARP inhibitors in advanced high-grade serous ovarian cancer according to BRCA domain mutations and mutation type 3
How SARS-CoV-2 Infection Impacts the Management of Patients with Vulvar Cancer: Experience in a Third-Level Hospital of Southern Italy 3
Corrigendum to 'Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)': [ESMO Open Volume 6, Issue 2, April 2021, 100054] 3
miRNAs in the Box: Potential Diagnostic Role for Extracellular Vesicle-Packaged miRNA-27a and miRNA-128 in Breast Cancer 3
Imaging tests in staging and surveillance of non-metastatic breast cancer: changes in routine clinical practice and cost implications 3
Palbociclib added to ongoing endocrine therapy for hormone receptor-positive HER2-negative metastatic breast cancer: A case report series 2
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 2
The Evolving Role of the Estrogen Receptor Mutations in Endocrine Therapy-Resistant Breast Cancer 2
High FOXA1 levels induce ER transcriptional reprogramming, a pro-metastatic secretome, and metastasis in endocrine-resistant breast cancer 2
TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 vs. 24 Weeks in Patients with HER2-positive Breast Cancer 2
Prevalence of Sarcopenia in Women with Breast Cancer 2
PIK3CA testing in hormone receptor-positive/HER2-negative metastatic breast cancer: real-world data from Italian molecular pathology laboratories 2
The changing role of ER in endocrine resistance 2
Safety and immunogenicity of the COVID-19 vaccine BNT162b2 for patients with breast and gynecological cancer on active anticancer therapy: Results of a prospective observational study 2
Interferon Signaling in Estrogen Receptor-positive Breast Cancer: A Revitalized Topic 2
Increased lysosomal biomass is responsible for the resistance of triple-negative breast cancers to CDK4/6 inhibition 2
In-house homologous recombination deficiency testing in ovarian cancer: a multi-institutional Italian pilot study 2
ESR1 mutations-a mechanism for acquired endocrine resistance in breast cancer 2
Triple-negative breast cancers: Biomarkers and outcomes 2
Towards personalized treatment for early stage HER2-positive breast cancer 2
New steps on an old path: Novel estrogen receptor inhibitors in breast cancer 2
Exploring the interplay between Kaposi's sarcoma and SARS‐CoV‐2 infection: A case series and systematic review 2
A CTC-Cluster-Specific Signature Derived from OMICS Analysis of Patient-Derived Xenograft Tumors Predicts Outcomes in Basal-Like Breast Cancer 2
Extended Adjuvant Endocrine Treatment in Luminal Breast Cancers in the Era of Genomic Tests 2
Nab-paclitaxel for the management of triple-negative metastatic breast cancer: a case study 2
Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: A propensity score analysis 2
Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up 2
Central obesity, body mass index, metabolic syndrome and mortality in Mediterranean breast cancer patients 2
Combined effect of obesity and diabetes on early breast cancer outcome: A prospective observational study 2
Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI) 2
COVID-19 in patients with thymic epithelial tumors with or without Good's syndrome: a single-center retrospective study 2
Molecular mechanism and clinical implications of endocrine therapy resistance in breast cancer 2
Luminal-like HER2-negative stage IA breast cancer: a multicenter retrospective study on long-term outcome with propensity score analysis 2
Brca1/2 ngs somatic testing in clinical practice: a short report 2
Insight on the Role of Leptin: A Bridge from Obesity to Breast Cancer 2
Case Report: Detection of a Novel Germline PALB2 Deletion in a Young Woman With Hereditary Breast Cancer: When the Patient's Phenotype History Doesn't Lie 2
Resistance to Anti-HER2 Therapies in Breast Cancer 2
A novel role of ADGRF1 (GPR110) in promoting cellular quiescence and chemoresistance in human epidermal growth factor receptor 2-positive breast cancer 2
Neratinib in HER2-Positive Breast Cancer Patients 2
The Epithelial-Stromal Interaction as a Potential Target for Breast Cancer Treatment 1
HER2-enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade 1
Immune Response Against Head and Neck Cancer: Biological Mechanisms and Implication on Therapy 1
Pretreatment Serum Concentration of Vitamin D and Breast Cancer Characteristics: A Prospective Observational Mediterranean Study 1
Enhancer reprogramming driven by high-order assemblies of transcription factors promotes phenotypic plasticity and breast cancer endocrine resistance 1
Modeling the Prognostic Impact of Circulating Tumor Cells Enumeration in Metastatic Breast Cancer for Clinical Trial Design Simulation 1
GMO-Gestione Malattie Oncologiche in Regione Campania 1
Low PETN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer 1
Multi-gene panel testing increases germline predisposing mutations' detection in a cohort of breast/ovarian cancer patients from Southern Italy 1
MITO END-3: efficacy of avelumab immunotherapy according to molecular profiling in first-line endometrial cancer therapy 1
Molecular mechanisms of endocrine resistance 1
Treatment landscape of triple-negative breast cancer — expanded options, evolving needs 1
Evolving treatments and outcomes in HER2-Positive metastatic breast cancer: Data from the GIM14/BIOMETA study 1
Optimising triage procedures for patients with cancer needing active anticancer treatment in the COVID-19 era 1
GPCRs profiling and identification of GPR110 as a potential new target in HER2+ breast cancer 1
Estrogen-induced transcription at individual alleles is independent of receptor level and active conformation but can be modulated by coactivators activity 1
Think “HER2” different: integrative diagnostic approaches for HER2-low breast cancer 1
Overcoming treatment resistance in HER2-positive breast cancer: potential strategies 1
Ribociclib in newly diagnosed hepatitis B infection: A case report 1
Unlocking the potential of Molecular Tumor Boards: from cutting-edge data interpretation to innovative clinical pathways 1
Ribociclib in HR+/HER2− Advanced or Metastatic Breast Cancer Patients 1
What medical oncologist residents think about the Italian speciality schools: A survey of the Italian Association of Medical Oncology (AIOM) on educational, clinical and research activities 1
Blockade of AP-1 potentiates endocrine therapy and overcomes resistance 1
Analysis of circulating extracellular vesicle derived microRNAs in breast cancer patients with obesity: a potential role for Let-7a 1
Metabolic syndrome and early stage breast cancer outcome: results from a prospective observational study 1
Editorial: Molecular predictive pathology in gynecologic malignancies 1
Circulating tumor cell investigation in breast cancer patient-derived xenograft models by automated immunofluorescence staining, image acquisition, and single cell retrieval and analysis 1
Embryonic transcription factor SOX9 drives breast cancer endocrine resistance 1
A review of the use of next generation sequencing methodologies to identify biomarkers of resistance to CDK4/6 inhibitors in ER+/HER2- breast cancer 1
Tamoxifen resistance in breast cancer is regulated by the EZH2–ERa–GREB1 transcriptional axis 1
Metabolic and anthropometric changes in early breast cancer patients receiving adjuvant therapy 1
PTK6 regulates growth and survival of endocrine therapyresistant ER+ breast cancer cells 1
Impact of a cardio-oncology unit on prevention of cardiovascular events in cancer patients 1
FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer 1
Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer 1
De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance 1
Prognostic Relevance of Progesterone Receptor Levels in Early Luminal-Like HER2 Negative Breast Cancer Subtypes: A Retrospective Analysis 1
Targeting the Mevalonate Pathway to Overcome Acquired Anti-HER2 Treatment Resistance in Breast Cancer 1
Totale 157
Salva come PNG Salva come JPEG
Categoria #
all - tutte 951
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 951
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2024/202591 0 0 0 0 0 0 0 0 0 0 0 91
2025/202666 43 13 10 0 0 0 0 0 0 0 0 0
Totale 157